STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1	Title and Abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	1	Abstract
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2	However, the disadvantages of detective technology have limited their widespread application.
	3	State specific objectives, including any prespecified hypotheses	2	The present study aimed to comprehensively explore the prognostic value of SII in patients with
Methods				
Study design	4	Present key elements of study design early in the paper	3	we incorporated a total of 208 adult GBM patients
	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	3,4	Inclusion and exclusion criteria; Data collection
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	3,4	Inclusion and exclusion criteria; Data collection

		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	UA	/
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4	Data collection
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	3,4	Inclusion and exclusion criteria Data collection
Bias	9	Describe any efforts to address potential sources of bias	3,4	Inclusion and exclusion criteria Statistical analysis
	10	Explain how the study size was arrived at	3	we incorporated a total of 208 adult GBM patients

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	4	Statistical analysis
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	4	Statistical analysis
		(*b*) Describe any methods used to examine subgroups and interactions	4	Statistical analysis
		(*c*) Explain how missing data were addressed	3,4	Study cohort; Statistical analysis
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	3,4	Inclusion and exclusion criteria; Data collection
		(*e*) Describe any sensitivity analyses	NA	/
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5,6	Clinical characteristics
		(b) Give reasons for non-participation at each stage	5,6	Clinical characteristics
		(c) Consider use of a flow diagram	/	/
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5,6	Clinical characteristics
		(b) Indicate number of participants with missing data for each variable of interest	5	Results (Table 1)
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	4	The end date of follow-up was September 31, 2022.
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	4-11	Results
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	/	/
		Cross-sectional study—Report numbers of outcome events or summary measures	/	/
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7,8	Prognostic significance of peripheral inflammatory markers

	(*b*) Report category boundaries when continuous variables were categorized	7	The optimal cutoff value for each marker was determined using X-tile software.
	(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	/	/

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	4-11	Results
Discussion				
Key results	18	Summarise key results with reference to study objectives	12	In this study
	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13	There are also some limitations of our present study.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14	Conclusion
Generalisability	21	Discuss the generalisability (external validity) of the study results	13	There are also some limitations of our present study.
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14	Acknowledgements

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.